NEXGEL (NXGL) - EV/EBITDA Multiple

NEXGEL Inc - graphic logo of issuer NXGL

The NEXGEL, Inc. (NXGL) price chart demonstrates an EV/EBITDA ratio of 0.00. The business's financial stability relies on the supply of patches and dressings to retailers while maintaining strict monitoring of material costs. The organization generates revenue through the sale of high-efficiency hydrogel products to clinics and pharmacies. Its development vector is aimed at penetrating new medical niches to systematically capture the specialized equipment segment.

NXGL NEXGEL, Inc: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/11/2026

Analytical breakdowns for nexgel.com (NXGL)

- stock price and consensus target price:
Stock Quotes NEXGEL, Inc|NXGL - Fair Value Consensus
- market capitalization indicators:
Market Capitalization NEXGEL Inc|NXGL - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share NEXGEL|NXGL - Accounting Capitalization|Market Value to Book Value Ratio nexgel.com|NXGL - Company Total Asset Base
- company liabilities and liquidity data:
Total Debt to Equity Ratio NEXGEL, Inc.|NXGL - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity NEXGEL|NXGL - Aggregate Debt Obligations|Debt to Book Value NEXGEL Inc|NXGL - Company Long-Term Debts|Company Short-Term Debt NEXGEL|Quick Ratio nexgel.com
- business earnings and investment ratios data:
NXGL - Company Net Income|Expected Profit NEXGEL, Inc.|NXGL - Price to Earnings Multiple|Projected Price to Earnings NEXGEL, Inc.|NXGL - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NEXGEL Inc|NXGL - Operating income before deduction of amortization|Earnings per share for the last twelve months NEXGEL|NXGL - Earnings per share for the last 12 months|Quarterly EPS earnings growth nexgel.com|NXGL - Earnings per share growth rate in current year|Expected earnings per share growth for next year NEXGEL, Inc.
Summary company analysis:NEXGEL, Inc (NXGL)
Manufactured products of NEXGEL

The multiple compares the total enterprise value, including net debt, to its operating profit before depreciation and amortization, allowing for an assessment of the real value of assets without the influence of the tax regime. By analyzing the EV/EBITDA ratio of the business, an investor separates the fundamental stability of NEXGEL (NXGL) from market noise, evaluating the efficiency of medical patch production while accounting for environmental control and emission purification costs.

Competitors of NEXGEL, Inc.

Intuitive Surgical Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation DHR|Becton Dickinson & Co - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio steris.com STE|West Pharmaceutical Services, Inc. (WST) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BAX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Masimo Personal Health|Stevanato Group Corp (STVN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TFX (Teleflex Incorporated)|Enterprise Value to Operating Income Before Depreciation Ratio MMSI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Envista NVST|Business Value to Operating Income Before Depreciation ICUI|XRAY: Enterprise Value to EBITDA Ratio|LMAT - EV/EBITDA Multiple|AtriCure, Inc. (ATRC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio staar.com|NAGE (ChromaDex Corp.) - EV/EBITDA Multiple|Company Value to EBITDA ZimVie Inc ZIMV|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AngioDynamics Corp (ANGO)|Cerus Inc - Enterprise Value to Operating Income Before Depreciation|Alpha Teknova, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MGRM (monogramorthopedics.com)|STSS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio InfuSystem Holdings INFU|Utah Medical (UTMD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation KRMD|NYXH (Nyxoah S.A.) - EV/EBITDA Multiple|Company Value to EBITDA microbotmedical.com MBOT|Enterprise Value to EBITDA Ratio PDEX (Pro-Dex)|Zentek Ltd - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ELUT (Elutia Corp)|Enterprise Value to EBITDA Multiple Milestone Scientific Corporation|Retractable Tech - EV/EBITDA Multiple|Company Value to EBITDA Harvard Bioscience Inc.|Femasys (FEMY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MHUA (Meihua Medical Technologies Co., Ltd.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio POAI|CJMB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATRI|Total Company Value to Operating Income Before Depreciation Ratio neurometrix.com